Skip to Content
Discovering the causes of cancer and the means of prevention

Publications Search - Abstract View

Title: Immunostaining to identify molecular subtypes of diffuse large B-cell lymphoma in a population-based epidemiologic study in the pre-rituximab era.
Authors: Morton LM,  Cerhan JR,  Hartge P,  Vasef MA,  Neppalli VT,  Natkunam Y,  Dogan A,  Dave BJ,  Jain S,  Levy R,  Lossos IS,  Cozen W,  Davis S,  Schenk MJ,  Maurer MJ,  Lynch CF,  Rothman N,  Chatterjee N,  Yu K,  Staudt LM,  Weisenburger DD,  Wang SS
Journal: Int J Mol Epidemiol Genet
Date: 2011 Aug 30
Branches: BB, EBP, OEEB, REB
PubMed ID: 21915363
PMC ID: PMC3166152
Abstract: Gene expression profiling studies have distinguished diffuse large B-cell lymphomas (DLBCLs) by cell of origin, with distinct pathogenetic mechanisms and prognosis. We attempted to identify DLBCL molecular subtypes in an epidemiologic study of 214 DLBCL patients diagnosed during 1998-2000 with archival tissues to investigate etiology. Immunohistochemical staining for CD10, BCL6, LMO2, MUM1/IRF4, and BCL2 and fluorescence in situ hybridization for t(14;18) were conducted, with ≥93% blinded duplicate agreement. CD10, LMO2, and BCL2 expression was similar to previous reports (32%, 44%, and 44% of DLBCLs, respectively), but BCL6 and MUM1/IRF4 expression was lower than expected (29% and 5%, respectively). We classified 112/214 (52%) cases as germinal center B-cell-like DLBCL (GCB-DLBCL; Hans et al., Blood 2004; CD10+ or CD10-/BCL6+/MUM1-), with no difference in prognosis compared with non-GCB-DLBCL (Cox regression, P=0.48). Comparing other GCB correlates, LMO2 expression and t(14;18) were more common but not exclusive to GCB-DLBCL as defined in our study, whereas BCL2 expression did not differ between DLBCL molecular subtypes. We could not confidently identify patients with GCB-DLBCL using these immunohistochemistry-based markers on archival tissues.